Sign Up to like & get
recommendations!
0
Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.3668
Abstract: Background: In the INBUILD trial in patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo over 52 weeks in the overall population and in the subgroup…
read more here.
Keywords:
dmards glucocorticoids;
boehringer ingelheim;
disease;
glucocorticoids baseline ... See more keywords